UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 8 von 117
Datensatz exportieren als...
BibTeX
A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease
Movement disorders, 2010-08, Vol.25 (11), p.1670-1674
Snow, Barry J.
Rolfe, Fiona L.
Lockhart, Michelle M.
Frampton, Christopher M.
O'Sullivan, John D.
Fung, Victor
Smith, Robin A.J.
Murphy, Michael P.
Taylor, Kenneth M.
2010
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Snow, Barry J.
Rolfe, Fiona L.
Lockhart, Michelle M.
Frampton, Christopher M.
O'Sullivan, John D.
Fung, Victor
Smith, Robin A.J.
Murphy, Michael P.
Taylor, Kenneth M.
Titel
A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease
Ist Teil von
Movement disorders, 2010-08, Vol.25 (11), p.1670-1674
Ort / Verlag
Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Erscheinungsjahr
2010
Quelle
MEDLINE
Beschreibungen/Notizen
Multiple lines of evidence point to mitochondrial oxidative stress as a potential pathogenic cause for Parkinson's disease (PD). MitoQ is a powerful mitochondrial antioxidant. It is absorbed orally and concentrates within mitochondria where it has been shown to protect against oxidative damage. We enrolled 128 newly diagnosed untreated patients with PD in a double‐blind study of two doses of MitoQ compared with placebo to explore the hypothesis that, over 12 months, MitoQ would slow the progression of PD as measured by clinical scores, particularly the Unified Parkinson Disease Rating Scale. We showed no difference between MitoQ and placebo on any measure of PD progression. MitoQ does not slow the progression of PD, and this finding should be taken into account when considering the oxidative stress hypothesis for the pathogenesis of PD. © 2010 Movement Disorder Society
Sprache
Englisch
Identifikatoren
ISSN: 0885-3185
eISSN: 1531-8257
DOI: 10.1002/mds.23148
Titel-ID: cdi_crossref_primary_10_1002_mds_23148
Format
–
Schlagworte
Adult
,
Aged
,
Antioxidants - therapeutic use
,
Biological and medical sciences
,
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
,
Dose-Response Relationship, Drug
,
Double-Blind Method
,
Female
,
Humans
,
Male
,
Medical sciences
,
Middle Aged
,
mitochondria
,
MitoQ
,
Neurology
,
neuroprotection
,
Organophosphorus Compounds - therapeutic use
,
oxidative damage
,
Parkinson Disease - drug therapy
,
Time Factors
,
Treatment Outcome
,
Ubiquinone - analogs & derivatives
,
Ubiquinone - therapeutic use
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX